End-of-day quote
Shanghai S.E.
06:00:00 2024-04-29 pm EDT
|
5-day change
|
1st Jan Change
|
16.12
CNY
|
+0.06%
|
|
+3.33%
|
-33.42%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11,231
|
28,827
|
46,842
|
35,397
|
21,777
|
14,500
|
-
|
-
|
Enterprise Value (EV)
1 |
11,231
|
28,827
|
46,842
|
35,397
|
21,777
|
14,500
|
14,500
|
14,500
|
P/E ratio
|
46.5
x
|
76.2
x
|
74
x
|
38.2
x
|
20.9
x
|
11.5
x
|
9.6
x
|
9.32
x
|
Yield
|
-
|
-
|
0.44%
|
0.94%
|
2.07%
|
3.01%
|
3.5%
|
4.22%
|
Capitalization / Revenue
|
5.57
x
|
10.9
x
|
11.5
x
|
6.5
x
|
3.94
x
|
2.3
x
|
2
x
|
1.82
x
|
EV / Revenue
|
5.57
x
|
10.9
x
|
11.5
x
|
6.5
x
|
3.94
x
|
2.3
x
|
2
x
|
1.82
x
|
EV / EBITDA
|
23.6
x
|
40.7
x
|
44.8
x
|
24.4
x
|
14
x
|
8.12
x
|
6.83
x
|
6.09
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
3.93
x
|
9.35
x
|
10.2
x
|
6.68
x
|
2.57
x
|
1.56
x
|
1.4
x
|
1.26
x
|
Nbr of stocks (in thousands)
|
805,662
|
805,235
|
832,596
|
834,255
|
899,486
|
899,486
|
-
|
-
|
Reference price
2 |
13.94
|
35.80
|
56.26
|
42.43
|
24.21
|
16.12
|
16.12
|
16.12
|
Announcement Date
|
4/8/20
|
4/27/21
|
4/19/22
|
4/27/23
|
4/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,017
|
2,647
|
4,063
|
5,445
|
5,523
|
6,294
|
7,251
|
7,954
|
EBITDA
1 |
476.4
|
708.9
|
1,045
|
1,452
|
1,554
|
1,787
|
2,122
|
2,381
|
EBIT
1 |
285.4
|
456.1
|
753.6
|
1,108
|
1,176
|
1,391
|
1,647
|
1,817
|
Operating Margin
|
14.15%
|
17.23%
|
18.55%
|
20.35%
|
21.29%
|
22.1%
|
22.72%
|
22.84%
|
Earnings before Tax (EBT)
1 |
286.9
|
449.9
|
744.7
|
1,104
|
1,181
|
1,390
|
1,646
|
1,816
|
Net income
1 |
237.8
|
380.6
|
633.9
|
920.9
|
1,033
|
1,259
|
1,513
|
1,556
|
Net margin
|
11.79%
|
14.38%
|
15.6%
|
16.91%
|
18.71%
|
20%
|
20.87%
|
19.56%
|
EPS
2 |
0.3000
|
0.4700
|
0.7600
|
1.110
|
1.160
|
1.398
|
1.680
|
1.730
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
0.2500
|
0.4000
|
0.5000
|
0.4850
|
0.5650
|
0.6800
|
Announcement Date
|
4/8/20
|
4/27/21
|
4/19/22
|
4/27/23
|
4/8/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
8.52%
|
12.9%
|
15.1%
|
18.7%
|
13.1%
|
14.4%
|
15.3%
|
13.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
10.5%
|
12.3%
|
-
|
9.79%
|
10.5%
|
10.5%
|
Assets
1 |
-
|
-
|
6,021
|
7,477
|
-
|
12,864
|
14,476
|
14,866
|
Book Value Per Share
2 |
3.540
|
3.830
|
5.500
|
6.350
|
9.410
|
10.40
|
11.50
|
12.80
|
Cash Flow per Share
2 |
0.6900
|
0.5000
|
0.8100
|
1.470
|
1.510
|
1.730
|
1.980
|
2.280
|
Capex
1 |
313
|
316
|
572
|
705
|
925
|
739
|
1,126
|
1,241
|
Capex / Sales
|
15.53%
|
11.93%
|
14.07%
|
12.95%
|
16.75%
|
11.74%
|
15.53%
|
15.61%
|
Announcement Date
|
4/8/20
|
4/27/21
|
4/19/22
|
4/27/23
|
4/8/24
|
-
|
-
|
-
|
Last Close Price
16.12
CNY Average target price
23.2
CNY Spread / Average Target +43.94% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.42% | 2B | | +26.08% | 662B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | -3.40% | 157B |
Other Pharmaceuticals
|